Sugi Predict

Sugi Predict / Compounds / SCHEMBL221280

SCHEMBL221280

SCHEMBL221280

O=C1Cc2ccc(Cl)cc2N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 4/20 1.00
▸ CMA1 P23946 2/20 1.00
▸ EIF2AK2 P19525 1/20 0.59
▸ PGR P06401 1/20 0.54
▸ PDK2 Q15119 1/20 0.53
▸ TDP2 O95551 3/20 0.53
▸ HTR3E A5X5Y0 1/20 0.47
▸ HTR3B O95264 1/20 0.47
▸ HTR3A P46098 1/20 0.47
▸ HTR3D Q70Z44 1/20 0.47
▸ HTR3C Q8WXA8 1/20 0.47
▸ CCNB2 O95067 2/20 0.47
▸ CDK1 P06493 2/20 0.47
▸ CCNB1 P14635 2/20 0.47
▸ GSK3B P49841 2/20 0.47
▸ CDK5 Q00535 2/20 0.47
▸ CDK5R1 Q15078 2/20 0.47
▸ CCNB3 Q8WWL7 2/20 0.47
▸ CRBN Q96SW2 2/20 0.47
▸ HTR5A P47898 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29908519 1.00 AHR (1.00) AHRCMA1EIF2AK2PGRPDK2
Hydrochloric Acid SCHEMBL29594534 0.98 AHR (0.96) AHRCMA1EIF2AK2PGRPDK2
SCHEMBL8584695 0.93 AHR (0.86) AHRCMA1EIF2AK2PGRPDK2
Ethyl Chloride SCHEMBL5152686 0.91 AHR (0.83) AHRCMA1EIF2AK2PGRPDK2
SCHEMBL154614 0.84 AHR (1.00) AHRCMA1EIF2AK2PGRPDK2
Tert-Butyl Formate SCHEMBL27929883 0.83 AHR (0.69) AHRCMA1EIF2AK2PGRPDK2
SCHEMBL29754265 0.82 AHR (0.70) AHRCMA1HTR3EHTR3BHTR3A
SCHEMBL2395389 0.82 AHR (0.70) AHRCMA1HTR3EHTR3BHTR3A
SCHEMBL31734655 0.82 AHR (0.69) AHRCMA1PGRTDP2CCNB2
SCHEMBL10711869 0.81 PGR (0.78) AHRCMA1EIF2AK2PGRTDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 691 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010817-A Preparation method of 4-chloro-5- (2-chloroethyl) indol-2-one 河北科技大学 2026-05-12 — — CN claimed
CN-117517501-A Ziprasidone hydrochloride, synthesis intermediate thereof and liquid chromatography detection method of impurities 湖南省湘中制药有限公司 2024-02-06 — — CN claimed
CN-112724066-B Dihalogen impurity in ziprasidone hydrochloride intermediate and preparation method thereof 海南鑫开源医药科技有限公司 2022-10-21 — — CN claimed
CN-112961150-A Impurities in ziprasidone hydrochloride and preparation method thereof 海南鑫开源医药科技有限公司 2021-06-15 — — CN claimed
CN-112778298-A Impurities in ziprasidone hydrochloride and preparation method thereof 海南鑫开源医药科技有限公司 2021-05-11 — — CN claimed
CN-112724066-A Dihalogen impurity in ziprasidone hydrochloride intermediate and preparation method thereof 海南鑫开源医药科技有限公司 2021-04-30 — — CN claimed
CN-106478486-A A kind of β hydroxyl alpha amino acid ester derivant and its synthetic method and application 华东师范大学 2017-03-08 — — CN claimed
US-20160075660-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2016-03-17 — — US claimed
CN-102797043-B Medicinal molecular fragment library and construction process thereof Tianli (Tianjin) Technology Co., Ltd. (CN) 2015-11-25 — — CN claimed
CN-104744338-A Method for synthesizing 6-chlorhydroxyl indole TIANJIN WEIZHI FINE CHEMICAL CO LTD 2015-07-01 — — CN claimed
US-6469181-B1 PREPARING 2-OXINDOLES AND N-HYROXY-2- OXINDOLES VIA REDUCTION OF 2-NITROARYLMALONATE DIESTERS WITHOUT ISOLATION OF INTERMEDIATES CATALYTICA, INC. 2002-10-22 — — US claimed
US-6458168-B1 Hair dyeing method using an aliphatic cationic amine and compound chosen from an aldehyde, a ketone, a quinone, a di-imino-isoindoline, and a 3-aminoisoindolone derivative L'OREAL S.A. (FR) 2002-10-01 — — US claimed
US-6451067-B1 HAIR DYE MIXTURE L'OREAL S.A. (FR) 2002-09-17 — — US claimed
CN-1078590-C Process for preparing 2-oxindoles and N-hydroxy-2-oxindoles CATALYTICA INC (US) 2002-01-30 — — CN claimed
EP-1165513-A1 INDOLINONE COMPOUNDS AS KINASE INHIBITORS Sugen, Inc. (US) 2002-01-02 — — EP claimed
WO-2000056709-A1 INDOLINONE COMPOUNDS AS KINASE INHIBITORS SUGEN, INC. (US) 2000-09-28 — — WO claimed
EP-0809631-A4 PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES CATALYTICA INC (US) 1998-07-08 — — EP claimed
CN-1177347-A Process for preparing 2 -oxindoles and N -hydroxy -2 -oxindoles CATALYTICA INC (US) 1998-03-25 — — CN claimed
EP-0809631-A1 PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES CATALYTICA, INC. (US) 1997-12-03 — — EP claimed
WO-1996023770-A1 PROCESS FOR PREPARING 2-OXINDOLES AND N-HYDROXY-2-OXINDOLES CATALYTICA, INC. (US) 1996-08-08 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160075660-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO HTR5A, HTR2A, HTR2B AHR 476/4885CMA1 2839/4885EIF2AK2 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.